United States Antacids - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states antacids market size is projected to expand from USD 2.75 billion in 2025 and USD 2.86 billion in 2026 to USD 3.45 billion by 2031, registering a CAGR of 3.85% between 2026 to 2031. This report is Segmented by Formulation Type (Tablets, Liquids, Powders, Gummies/Chewable Soft-Gels, Effervescent Granules), Active Ingredient (Calcium Carbonate, Magnesium, Aluminium, Sodium Bicarbonate, Alginate-Based, Combinations), Indication (Heartburn, GERD, Peptic Ulcer, Functional Dyspepsia), and Distribution Channel (Retail Pharmacies, E-Commerce, Hospital Pharmacies). Forecasts in Value (USD).

United States Antacids Market Trends and Insights

Aging Population And Sustained Heartburn Prevalence

The US antacids market is supported by the speed of demographic aging, not only by the size of the older population. All baby boomers will be age 65 or older by 2030, which means the US antacids market will keep drawing demand from an age group with higher exposure to reflux and chronic digestive discomfort. Population studies continue to place GERD prevalence in North America at 18.1% to 27.8%, and reflux oesophagitis incidence peaks between ages 60 and 70. This matters because older users tend to repurchase more regularly, which gives the US antacids market a dependable demand floor that is less exposed to the swings seen in more discretionary consumer categories. Brands that focus too narrowly on younger clean-label buyers risk missing a loyal older customer base that still values familiar relief formats, lower-sodium options, and easy-to-swallow products.

Unhealthy Diets And Episodic Reflux Triggers

The US antacids market also benefits from a dietary pattern that keeps episodic reflux active across income groups and age bands. Adults in the United States derived 53% of daily calories from ultra-processed foods between 2021 and 2023, which is associated with higher body weight, greater intra-abdominal pressure, and more frequent acid reflux triggers. The CDC reported in December 2025 that every state and territory had adult obesity prevalence of at least 25%, with the Midwest at 35.8% and the South at 34.6%. The USDA and HHS dietary guidance also continued to emphasize the health burden linked to ultra-processed food patterns, which reinforces the persistence of reflux-provoking diets rather than a temporary spike in poor eating habits. This keeps the US antacids market supplied with repeat demand from consumers who move from occasional heartburn to more frequent self-treatment over time.

Switching To PPIs And H2 Blockers

Therapeutic substitution remains the primary restraint on the US antacids market because chronic heartburn sufferers often look for longer-lasting acid suppression than a standard antacid provides. PPIs are positioned around 24-hour suppression and H2 blockers around longer relief windows than antacids, so frequent sufferers can move up the treatment ladder when symptoms become more regular. This creates a real retention challenge for the US antacids market, especially among consumers who experience heartburn several times each week and begin to see rapid relief as less important than duration. At the same time, clinical discussion around PPI use has become more active, and step-down treatment remains part of the conversation for appropriate patients who do not need continuous high-intensity suppression. That means the US antacids market is not facing a one-way exit into other therapies, but brands still need to explain where antacids fit in a broader symptom-management pathway if they want to retain users over time.

Other drivers and restraints analyzed in the detailed report include:

• OTC Accessibility And Self-Medication Behavior
• Retail Pharmacy And E-Commerce Expansion
• Safety Concerns With Chronic Antacid Use

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Tablets accounted for 42.31% of the US antacids market share in 2025, and that lead came from long-standing consumer familiarity, broad shelf placement, and manufacturing scale that supports competitive pricing. Chewable tablet products from established brands remain embedded across pharmacy planograms and mass retail aisles, which keeps the format highly visible for both planned and impulse purchases. Liquids and suspensions continue to serve older adults and consumers with swallowing difficulty, which gives them a stable role despite the dominance of solid formats. Powders and effervescent granules still address a smaller convenience-oriented need state for users who want portability or fast mixing.

Gummies and chewable soft-gels are the fastest-growing formulation segment, with a 6.38% CAGR expected through 2031. Their rise reflects a broader format shift that has already reshaped vitamins and supplements, where consumers increasingly prefer easier taste profiles and more approachable dosage forms. Younger adults, especially those aged 18 to 45, show higher trial rates for gummy-style products because they reduce the chalky texture associated with traditional antacid tablets. Quest Products reinforced that direction in May 2026 with the launch of OraHealth Antacid Melts, a stick-on product for nighttime heartburn relief that extends the US antacids market beyond the long-established tablet and liquid format set.

Calcium carbonate held 35.24% of active ingredient revenue in 2025, which kept it at the center of the US antacids industry because of low production cost, a familiar safety profile under labeled use, and well-established monograph compliance. Magnesium-based products held the next important position, supported by consumer recognition of their digestive effect at higher doses. Aluminium compounds remained less favored because long-running concern around tolerability and perception has weakened consumer appeal, even where the underlying discussion remains contested. Combination products such as calcium carbonate plus magnesium hydroxide continue to benefit from a broader buffering profile, but alginate-based products stand out as the fastest-growing group with a 7.52% CAGR through 2031.

Alginate products are gaining attention because they do not rely only on neutralizing acid, but also form a physical raft barrier above gastric contents. A 2025 Scientific Reports study found comparable efficacy between generic and original alginate formulations in PPI-refractory GERD patients, which gives the US antacids industry a stronger clinical basis for differentiated positioning. That distinction matters because brands can speak to a different mechanism of action without leaving the OTC channel or requiring a prescription step. Haleon is well placed in this part of the US antacids market through its global exposure to both TUMS and Gaviscon, yet the domestic opportunity remains open enough for specialists and direct-to-consumer brands to move first if larger players stay measured in their rollout.

Complete Report Scope:

• By Formulation Type
  • Tablets
  • Liquids / Suspensions
  • Powders
  • Gummies / Chewable Soft-Gels
  • Effervescent Granules
  • Other Formulations
• By Active Ingredient Type
  • Calcium Carbonate
  • Magnesium Compounds
  • Aluminium Compounds
  • Sodium Bicarbonate
  • Alginate-Based
  • Combination Preparations
• By Indication
  • Heartburn
  • Gastroesophageal Reflux Disease (GERD)
  • Peptic Ulcer-Related Acid Relief
  • Functional Dyspepsia
  • Other Indications
• By Distribution Channel
  • Retail Pharmacies & Drug Stores
  • E-Commerce
  • Hospital Pharmacies
  • Other Distribution Channels

List of Companies Covered in this Report:

• Albertsons Companies, Inc.
• Amazon.com
• Bayer
• Costco Wholesale Corporation
• CVS Health
• Haleon plc
• Infirst Healthcare USA
• Kenvue Inc.
• Kroger Co.
• LNK International, Inc.
• Major Pharmaceuticals
• Perrigo Company
• PL Developments, Inc.
• Procter & Gamble
• Target Corporation
• Walgreens Boots Alliance, Inc.
• Walmart Inc.
• Wonderbelly, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support